Advertisement

Immunomodulatory Effects of Blood Transfusion on Tumor Size, Metastasis, and Survival in Experimental Fibrosarcoma

  • Kamal Abdolmohammadi
  • Tayebeh Mahmoudi
  • Tohid Jafari-Koshki
  • Zuhair Mohammad Hassan
  • Ali Akbar Pourfathollah
Original Article
  • 24 Downloads

Abstract

In spite of efforts, blood transfusion is still accompanied with adverse effects such as transfusion-related immunomodulation (TRIM). The current study aimed to evaluate the effects of allogeneic, syngeneic, fresh and storage blood transfusion on the growth and metastasis of tumors and survival in fibrosarcoma bearing BALB/c mice. Twenty-five BALB/c mice were grouped into five groups of equal size. All groups were injected 1.2 × 106 WEHI-164 cells subcutaneously to induce fibrosarcoma tumor. After expansion of the tumor, in four groups (except for the control group), hemorrhage-induced anemia was developed. Twenty-four hours later, blood deficit was replaced by fresh allogeneic, storage allogeneic, fresh syngeneic and storage syngeneic blood transfusion, respectively. After a blood transfusion, for 13 days, the tumor size and survival of the mice were evaluated. In the day 20, the mice were sacrificed and their spleen tissues were evaluated for TRIM induced metastasis. Tumor size increase in the groups that received allogeneic (fresh and storage) and storage syngeneic blood transfusion was significantly higher than the control group (P value < 0.05). However, no significant difference was present in survival between the experiment groups and the control group. There was no metastasis in none of groups at the end of the study. Allogeneic and storage blood transfusion could have immunomodulatory effects such as increased tumor size. However, it seems that fresh and syngeneic blood transfusion have no effects on tumor growth in fibrosarcoma bearing mice. Further evidence may prove that more attention is warranted in blood transfusion into cancer cases.

Keywords

Blood transfusion Fibrosarcoma Immunomodulation 

Notes

Acknowledgements

The authors would like to thank Hasan Mohammad HosseiniAkbari for his help in histopathological examinations.

Author Contributions

AAP and ZMH and KA designed the study. KA performed laboratory works. KA and TM and TJK performed the statistical analysis and wrote the manuscript. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights

All procedures performed in studies involving animals were in accordance with the ethical standards of the Tarbiat Modares University.

References

  1. 1.
    Brown CJ, Navarrete CV (2011) Clinical relevance of the HLA system in blood transfusion. Vox Sang 101(2):93–105CrossRefPubMedGoogle Scholar
  2. 2.
    Vamvakas EC, Blajchman MA (2001) Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 97(5):1180–1195CrossRefPubMedGoogle Scholar
  3. 3.
    Lin H-S, Samy RN, Lum J, Dorie MJ, Terris DJ (2002) Effect of blood transfusion in an experimental sarcoma model. Arch Otolaryngol Head Neck Surg 128(3):308–312CrossRefPubMedGoogle Scholar
  4. 4.
    Sun K, D’Alessandro A, Xia Y (2017) Purinergic control of red blood cell metabolism: novel strategies to improve red cell storage quality. Blood Transfus 15(6):535PubMedPubMedCentralGoogle Scholar
  5. 5.
    Greenwalt T (1997) A short history of transfusion medicine. Transfusion 37(5):550–563CrossRefPubMedGoogle Scholar
  6. 6.
    Bilgin Y, Van de Watering L, Brand A (2011) Clinical effects of leucoreduction of blood transfusions. Neth J Med 69(10):441–450PubMedGoogle Scholar
  7. 7.
    Rice TC, Pugh AM, Caldwell CC, Schneider BSP (2017) Balance between the proinflammatory and anti-inflammatory immune responses with blood transfusion in sepsis. Crit Care Nurs Clin North Am 29(3):331–340CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dzik S (2000) Mechanisms underlying the immunomodulatory effect of allogeneic blood transfusion. Scientific basis of transfusion medicine: implications for clinical practice, 2nd edn. WB Saunders Company, Philadelphia, pp 444–454Google Scholar
  9. 9.
    Pereira A (2001) Deleterious consequences of allogeneic blood transfusion on postoperative infection: really a transfusion-related immunomodulation effect? Blood 98(2):498–500CrossRefPubMedGoogle Scholar
  10. 10.
    Salvatierra O Jr, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G et al (1980) Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg 192(4):543CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Alexander JW, Babcock GF, First MR, Davies CB, Madden RL, Munda R et al (1992) The induction of immunologic hypresponsiveness by preoperative donor-specific transfusions and cyclosporine in human cadaveric transplants. Transplantation 53(2):423–427CrossRefPubMedGoogle Scholar
  12. 12.
    Lapierre V, Aupérin A, Tiberghien P (1998) Transfusion-induced immunomodulation following cancer surgery: fact or fiction? JNCI J Natl Cancer Inst 90(8):573–580CrossRefPubMedGoogle Scholar
  13. 13.
    Hellings S, Blajchman MA (2009) Transfusion-related immunosuppression. Anaesth Intensive Care Med 10(5):231–234CrossRefGoogle Scholar
  14. 14.
    Clark DA, Gorczynski RM, Blajchman MA (2008) Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion 48(5):814–821CrossRefPubMedGoogle Scholar
  15. 15.
    Blumberg N, Heal JM (1994) Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 118(4):371–379PubMedGoogle Scholar
  16. 16.
    Heiss MM, Mempel W, Delanoff C, Jauch K-W, Gabka C, Mempel M et al (1994) Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 12(9):1859–1867CrossRefPubMedGoogle Scholar
  17. 17.
    Meng J, Lu X-B, Tang Y-X, Sun G-P, Li X, Yan Y-F et al (2013) Effects of allogeneic blood transfusion in patients with stage II colon cancer. Asian Pac J Cancer Prev 14(1):347–350CrossRefPubMedGoogle Scholar
  18. 18.
    Benson D, Barnett CC (2011) Perioperative blood transfusions promote pancreas cancer progression. J Surg Res 166(2):275–279CrossRefPubMedGoogle Scholar
  19. 19.
    Bordin J, Bardossy L, Blajchman M (1994) Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood 84(1):344–348PubMedGoogle Scholar
  20. 20.
    Hashemi SM, Hassan ZM, Soudi S, Ghazanfari T, Kheirandish M, Shahabi S (2007) Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice. Int Immunopharmacol 7(7):920–927CrossRefPubMedGoogle Scholar
  21. 21.
    Goubran HA, Elemary M, Radosevich M, Seghatchian J, El-Ekiaby M, Burnouf T (2016) Impact of transfusion on cancer growth and outcome. Cancer Growth Metastasis 9:1CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Muszynski JA, Spinella PC, Cholette JM, Acker JP, Hall MW, Juffermans NP et al (2017) Transfusion-related immunomodulation: review of the literature and implications for pediatric critical illness. Transfusion 57(1):195–206CrossRefPubMedGoogle Scholar
  23. 23.
    Atzil S, Arad M, Glasner A, Abiri N, Avraham R, Greenfeld K et al (2008) Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology 109(6):989–997CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ames S, Shelby J, Roberts L, Nelson E (eds) (1988) Factors in transfusion-related enhanced tumor growth. In: Transplantation proceedings. Elsevier, AtlantaGoogle Scholar
  25. 25.
    Newman E, Ho M, Heslin MJ, Chapman DS, Brennan MF (1996) The effect of blood transfusion on tumor growth in sarcoma-bearing rats. Ann Surg Oncol 3(1):74–79CrossRefPubMedGoogle Scholar
  26. 26.
    Dzik S, Aubuchon J, Jeffries L, Kleinman S, Manno C, Murphy MF et al (2000) Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 14(1):34–52CrossRefPubMedGoogle Scholar
  27. 27.
    Högman CF (1999) Storage of blood components. Curr Opin Hematol 6(6):427CrossRefPubMedGoogle Scholar
  28. 28.
    Dent L, Finlay-Jones J (1985) In vivo detection and partial characterization of effector and suppressor cell populations in spleens of mice with large metastatic fibrosarcomas. Br J Cancer 51(4):533CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Safford S, Oberley T, Urano M, Clair DS (1994) Suppression of fibrosarcoma metastasis by elevated expression of manganese superoxide dismutase. Can Res 54(16):4261–4265Google Scholar
  30. 30.
    English WR, Lunt SJ, Fisher M, Lefley DV, Dhingra M, Lee Y-C et al (2017) Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma. Can Res 77(10):2633–2646CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  • Kamal Abdolmohammadi
    • 1
    • 2
  • Tayebeh Mahmoudi
    • 3
  • Tohid Jafari-Koshki
    • 4
    • 5
  • Zuhair Mohammad Hassan
    • 2
  • Ali Akbar Pourfathollah
    • 2
  1. 1.Department of Immunology, School of MedicineTehran University of Medical SciencesTehranIran
  2. 2.Department of Immunology, Faculty of Medical SciencesTarbiat Modares UniversityTehranIran
  3. 3.Department of Immunology, Faculty of MedicineKurdistan University of Medical SciencesSanandajIran
  4. 4.Medical Education Research Center, Health Management and Safety Promotion Research InstituteTabriz University of Medical SciencesTabrizIran
  5. 5.Road Traffic Injury Research Center, Department of Statistics and Epidemiology, Faculty of HealthTabriz University of Medical SciencesTabrizIran

Personalised recommendations